Endothelial–Mesenchymal Transition Drives Expression of CD44 Variant and xCT in Pulmonary Hypertension
- 1 September 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 61 (3) , 367-379
Abstract
Pulmonary arterial hypertension (PAH) pathogenesis shares similarities with carcinogenesis. One CD44 variant (CD44v) isoform, CD44v8-10, binds to and stabilizes the cystine transporter subunit (xCT), producing reduced glutathione and thereby enhancing the antioxidant defense of cancer stem cells. Pharmacological inhibition of xCT by sulfasalazine suppresses tumor growth, survival, and resistance to chemotherapy. We investigated whether the CD44v–xCT axis contributes to PAH pathogenesis. CD44v was predominantly expressed on endothelial-to-mesenchymal transition (EndMT)–like cells in the neointimal layer of PAH affected pulmonary arterioles. In vitro, CD44 standard form and CD44v were induced as a result of EndMT. Among human pulmonary artery endothelial cells that have undergone EndMT, CD44v+ cells showed high levels of xCT expression on their cell surfaces and high concentrations of glutathione for survival. This made CD44v+ cells the most vulnerable target for sulfasalazine. CD44v+xCThi cells showed the highest expression levels of proinflammatory cytokines, antioxidant enzymes, antiapoptotic molecules, and cyclin-dependent kinase inhibitors. In the Sugen5416/hypoxia mouse model, CD44v+ cells were present in the thickened pulmonary vascular wall. The administration of sulfasalazine started either at the same time as “Sugen5416” administration (a prevention model) or after the development of pulmonary hypertension (a reversal model) attenuated the muscularization of the pulmonary vessels, decreased the expression of markers of inflammation, and reduced the right ventricular systolic pressure, while reducing CD44v+ cells. In conclusion, CD44v+xCThi cells appear during EndMT and in pulmonary hypertension tissues. Sulfasalazine is expected to be a novel therapeutic agent for PAH, most likely targeting EndMT-derived CD44v+xCThi cells.Keywords
This publication has 48 references indexed in Scilit:
- Molecular pathogenesis of pulmonary arterial hypertensionJournal of Clinical Investigation, 2012
- Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemiaNature Cell Biology, 2012
- Replicative Aging Induces Endothelial to Mesenchymal Transition in Human Aortic Endothelial Cells: Potential Role of InflammationJournal of Vascular Research, 2011
- Disruption of PPARγ/β-catenin–mediated regulation of apelin impairs BMP-induced mouse and human pulmonary arterial EC survivalJournal of Clinical Investigation, 2011
- PDGF-BB and TGF-β1 on cross-talk between endothelial and smooth muscle cells in vascular remodeling induced by low shear stressProceedings of the National Academy of Sciences, 2011
- Epigenetic Attenuation of Mitochondrial Superoxide Dismutase 2 in Pulmonary Arterial HypertensionCirculation, 2010
- Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodentsJournal of Clinical Investigation, 2009
- ESRP1 and ESRP2 Are Epithelial Cell-Type-Specific Regulators of FGFR2 SplicingMolecular Cell, 2009
- The β-catenin/TCF4 pathway modifies alternative splicing through modulation of SRp20 expressionRNA, 2008
- The Cancer Paradigm of Severe Pulmonary Arterial HypertensionAmerican Journal of Respiratory and Critical Care Medicine, 2008